Literature DB >> 9120257

Modulation of the p27kip1 cyclin-dependent kinase inhibitor expression during IL-4-mediated human B cell activation.

D A Blanchard1, M T Affredou, A Vazquez.   

Abstract

IL-4 activates resting B cells and, in conjunction with cosignals such as anti-IgM (anti-mu) Ab or CD40 ligand, modulates progression of B cells through the cell cycle, leading to proliferation. In this study, we show that the mitogenic combination of IL-4 and anti-mu Ab triggered induction of cyclin D3 and up-regulated cyclin-dependent kinase (cdk) 6 expression, whereas such regulation was not observed in B cells activated by IL-4 or anti-mu Ab alone. Furthermore, cyclin D3 immunoprecipitated fron as associated with cdk6, and the cyclin D3/cdk6 complex was able to phosphorylate recombinant retinoblastoma protein in vitro. In addition, B cells activated with either IL-4 or 1L-13 alone expressed a higher amount of p27kip1 (p27) cdk inhibitor than nonstimulated cells. In contrast, p27 expression was decreased when cells were activated with mitogenic combinations of IL-4 and anti-mu Ab or anti-CD40 mAb. We also observed that the IL-4-mediated inhibition of the proliferation of anti-mu/IL-2- or anti-mu/phorbol 12,13-dibutyrate-activated human leukemic B cells was associated with the maintenance of large amounts of p27 in these cells. These data suggest that IL-4 controls B cell proliferation by action during at least two steps of the regulation of the cell cycle, cyclin D3/cdk6 complex regulation and p27 inhibitor expression.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9120257

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Impaired immune responses and B-cell proliferation in mice lacking the Id3 gene.

Authors:  L Pan; S Sato; J P Frederick; X H Sun; Y Zhuang
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

2.  3BP2 deficiency impairs the response of B cells, but not T cells, to antigen receptor ligation.

Authors:  Miguel A de la Fuente; Lalit Kumar; Bao Lu; Raif S Geha
Journal:  Mol Cell Biol       Date:  2006-07       Impact factor: 4.272

3.  Regulation of memory B-cell survival by the BH3-only protein Puma.

Authors:  Cyril Clybouw; Silke Fischer; Marie Thérèse Auffredou; Patricia Hugues; Catherine Alexia; Philippe Bouillet; Martine Raphael; Gérald Leca; Andreas Strasser; David M Tarlinton; Aimé Vazquez
Journal:  Blood       Date:  2011-08-25       Impact factor: 22.113

4.  Stat proteins control lymphocyte proliferation by regulating p27Kip1 expression.

Authors:  M H Kaplan; C Daniel; U Schindler; M J Grusby
Journal:  Mol Cell Biol       Date:  1998-04       Impact factor: 4.272

5.  Clinicopathologic features of CDK6 translocation-associated B-cell lymphoproliferative disorders.

Authors:  Dong Chen; Mark E Law; Jason D Theis; Jeffrey D Gamez; Lynn B Caron; Julie A Vrana; Ahmet Dogan
Journal:  Am J Surg Pathol       Date:  2009-05       Impact factor: 6.394

6.  Cell proliferation and survival induced by Toll-like receptors is antagonized by type I IFNs.

Authors:  Uzma A Hasan; Christophe Caux; Ivan Perrot; Anne-Claire Doffin; Christine Menetrier-Caux; Giorgio Trinchieri; Massimo Tommasino; Jaromir Vlach
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-26       Impact factor: 11.205

Review 7.  Role of immune escape mechanisms in Hodgkin's lymphoma development and progression: a whole new world with therapeutic implications.

Authors:  Luis de la Cruz-Merino; Marylène Lejeune; Esteban Nogales Fernández; Fernando Henao Carrasco; Ana Grueso López; Ana Illescas Vacas; Mariano Provencio Pulla; Cristina Callau; Tomás Álvaro
Journal:  Clin Dev Immunol       Date:  2012-08-15

8.  The Pt(S-pr-thiosal)2 and BCL1 Leukemia Lymphoma: Antitumor Activity In Vitro and In Vivo.

Authors:  Zana Besser Silconi; Vesna Rosic; Sasa Benazic; Gordana Radosavljevic; Marina Mijajlovic; Jelena Pantic; Zoran R Ratkovic; Gordana Radic; Aleksandar Arsenijevic; Marija Milovanovic; Nebojsa Arsenijevic; Jelena Milovanovic
Journal:  Int J Mol Sci       Date:  2022-07-24       Impact factor: 6.208

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.